Enterostatin
(Synonyms: 人肠抑素) 目录号 : GC18105
A pentapeptide involved in the regulation of food intake
Cas No.:117830-79-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Enterostatin, human, mouse, rat is a pentapeptide that reduces fat intake.
In the perfused ratpancreas, Enterostatin, at 100 mM, inhibits the insulin response to 9 mM glucose (by 70%), 0.1 mM tolbutamide (by 40%), and 5 mM arginine (by 70%)[1].
Chronically, enterostatin reduces fat intake, bodyweight, and body fat. This response may involve multiple metabolic effects of enterostatin, which include a reduction of insulin secretion, an increase in sympathetic drive to brown adipose tissue, and the stimulation of adrenal corticosteroid secretion[2]. Enterostatin enhances memory consolidation after central or oral administration at a dose of 10 nmol/mouse or 300 mg/kg, respectively, in a step-through type passive avoidance test in mice[3]. A dose of 38 nmol of enterostatin gives a significant inhibition of high-fat food intake, while at a higher dose of 76 nmol the inhibiting effect is lost. During the first hour, after injection of enterostatin, there is even a slight increase in food intake[4].
References:
[1]. Silvestre RA, et al. Effect of enterostatin on insulin, glucagon, and somatostatin secretion in the perfused rat pancreas. Diabetes. 1996 Sep;45(9):1157-60.
[2]. Erlanson-Albertsson C, et al. Enterostatin--a peptide regulating fat intake. Obes Res. 1997 Jul;5(4):360-72.
[3]. Ohinata K, et al. Enterostatin (APGPR) enhances memory consolidation in mice. Peptides. 2007 Mar;28(3):719-21.
[4]. Sörhede M, et al. Enterostatin: a gut-brain peptide regulating fat intake in rat. J Physiol Paris. 1993;87(4):273-5.
| Cas No. | 117830-79-2 | SDF | |
| 别名 | 人肠抑素 | ||
| 化学名 | (S)-2-((S)-1-(2-((S)-1-((S)-2-aminopropanoyl)pyrrolidine-2-carboxamido)acetyl)pyrrolidine-2-carboxamido)-5-((diaminomethylene)amino)pentanoic acid | ||
| Canonical SMILES | O=C([C@H]1N(C([C@H](C)N)=O)CCC1)NCC(N2[C@H](C(N[C@H](C(O)=O)CCC/N=C(N)/N)=O)CCC2)=O | ||
| 分子式 | C21H36N8O6 | 分子量 | 496.57 |
| 溶解度 | Soluble to 0.70 mg/ml in sterile water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0138 mL | 10.0691 mL | 20.1381 mL |
| 5 mM | 0.4028 mL | 2.0138 mL | 4.0276 mL |
| 10 mM | 0.2014 mL | 1.0069 mL | 2.0138 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。